Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7829432 | 1.00 | HDAC1 (0.65) | HDAC1HDAC8HDAC2ALOX5HDAC6 | |
| SCHEMBL7832253 | 0.85 | MAPT (0.57) | HDAC1HDAC8HDAC2HDAC6HDAC3 | |
| SCHEMBL7821089 | 0.85 | MAPT (0.57) | HDAC1HDAC8HDAC2HDAC6HDAC3 | |
| SCHEMBL25008206 | 0.84 | HDAC1 (0.45) | HDAC1HDAC8HDAC2HDAC6HDAC3 | |
| SCHEMBL5197022 | 0.83 | CYP1A2 (0.55) | HDAC1HDAC8HDAC2HDAC6HDAC3 | |
| SCHEMBL11597016 | 0.83 | CYP1A2 (0.50) | HDAC1HDAC8HDAC2HDAC6HDAC3 | |
| SCHEMBL3380927 | 0.82 | HDAC1 (0.65) | HDAC1HDAC8HDAC2HDAC6HDAC3 | |
| SCHEMBL5199025 | 0.79 | CYP1A2 (0.60) | HDAC1HDAC8HDAC2HDAC6HDAC3 | |
| SCHEMBL7829868 | 0.79 | HDAC1 (1.00) | HDAC1HDAC8HDAC2ALOX5HDAC6 | |
| SCHEMBL3378763 | 0.79 | HDAC1 (1.00) | HDAC1HDAC8HDAC2ALOX5HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071620-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-8071620-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-7652036-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7652036-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| EP-0737671-B1 | Aromatic hydroxamic acid compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-12-12 | — | — | EP | disclosed |
| US-5804601-A | USEFUL FOR TREATING ALZHEIMER'S DISEASE, MULTIPLE SCLEROSIS, BACTERIAL OR VIRAL MENINGITIS, DOWN'S SYNDROME AND PARKINSON'S DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-08 | — | — | US | disclosed |
| EP-0737671-A2 | Aromatic hydroxamic acid compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1996-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | HDAC1, HDAC7, HDAC5 | HDAC1 1/4885HDAC8 4/4885HDAC2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.